LENZ THERAPEUTICS INC

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

09 مايو 2025 08:03:48 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

07 مايو 2025 15:05:01 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

06 مايو 2025 15:30:48 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

30 أبريل 2025 15:30:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

19 مارس 2025 15:05:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

11 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Host Commercial Day on April 15, 2025

03 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming Investor Conferences

24 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming Investor Conferences

12 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

06 نوفمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

30 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

27 أكتوبر 2024 20:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

21 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences

30 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming Investor Conferences

27 أغسطس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

14 أغسطس 2024 15:05:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

12 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

07 أغسطس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

15 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

10 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire